Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
The last earnings update was 34 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Fulcrum Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Fulcrum Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Fulcrum Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Fulcrum Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Fulcrum Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Fulcrum Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Fulcrum Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Fulcrum Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Fulcrum Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are -7.2117401840982E+18x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Robert J. Gould, Ph.D., has been Chief Executive Officer, President and Director of Fulcrum Therapeutics, Inc. since June 2016. Dr. Gould served as the Chief Executive Officer of Epizyme, Inc. from March 2010 to September 10, 2015 and its President from September 2014 to September 10, 2015, Interim Treasurer since October 1, 2014, Secretary until September 10, 2015 and Principal Financial Officer. He served as the Vice President of Licensing and External Research at Merck Research Labs until 2006 and President of Licensing and External Research. Dr. Gould served as Vice President of Basic Research at Merck Research Labs, where he oversaw strategic direction and drug discovery activities for multiple therapeutic areas, as well as MRL's centralized high throughput screening and imaging facilities. He served as Chairman of Scientific Advisory board at FORMA Therapeutics, Inc. since March 2009 and served as its Member of Scientific Advisory Board. He serves as a Director of HemoShear Therapeutics, LLC. He served as a Director of Novel Therapeutics, The Broad Institute of MIT and Harvard from 2006 to 2010. He served as Director of Epizyme, Inc. from March 2008 to October 20, 2016. Dr. Gould has published over 90 peer-reviewed publications and 16 patents. After post-doctoral studies at The Johns Hopkins University, Dr. Gould joined Merck Sharp and Dohme Research Labs where he remained until retiring and joining the Broad Institute. He obtained BA from Spring Arbor College, Michigan in 1976 and Ph.D. from The University of Iowa in 1981.
Insufficient data for Robert to compare compensation growth.
Robert's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Fulcrum Therapeutics management team is less than 2 years, this suggests a new team.
CEO, President & Director
Chief Operating Officer
Senior Vice President of Clinical Development
Vice President of Finance & Accounting
Chief Scientific Officer
Senior Vice President of Regulatory Affairs & Quality Assurance
Senior Vice President of Discovery
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Fulcrum Therapeutics board of directors is about average.
Board of Directors
Chairman of the Board
CEO, President & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. The company has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.